Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Possible Hereditary Link Between Ovarian and Testicular Cancers Observed

March 20, 2018
By Dave Levitan
Article

A registry study suggests that there may be a familial association between ovarian and testicular cancers.

A registry study suggests that there may be a familial association between ovarian and testicular cancers. In the study, men with testicular cancer were more likely to have a mother with ovarian cancer compared with men with other malignancies.

Testicular germ cell tumors (TGCT) are the most common malignancies among American men aged 15 to 44 years; family history of TGCT has been well established as a risk factor for these tumors. “Although familial TGCT studies have yet to characterize TGCT syndromic patterns, a biologically plausible link between TGCT and ovarian germ cell tumors has been posited,” wrote study authors led by Kirsten B. Moysich, PhD, of the Roswell Park Comprehensive Cancer Center in Buffalo.

The investigators conducted a study using data from the Familial Ovarian Cancer Registry to test for associations between ovarian cancer and TGCT. They included a total of 2,636 families with multiple cases of ovarian cancer. Results were published in Cancer Epidemiology.

The cohort contained 34 men with testicular cancer, and 2,894 men with non-testicular cancers. Of those 34 men, 24 had mothers with known ovarian cancer status, and 10 mothers (41.67%) had ovarian cancer while 14 did not. This meant that the men with testicular cancer were significantly more likely to have a mother with ovarian cancer compared with the men with other malignancies, with an odds ratio (OR) of 3.32 (95% CI, 1.46–7.55; P = .004). The same was true for having a sister with ovarian cancer, though this did not reach significance, with an OR of 1.66 (95% CI, 0.87–3.15; P = .124); of the 43 sisters of men with testicular cancer with known ovarian cancer status, 14 (32.56%) had ovarian cancer.

The men in the registry with testicular cancer fathered 13 daughters, but these daughters were either too young to be at risk for ovarian cancer, or lacked adequate follow-up. Four of 16 maternal grandmothers had ovarian cancer (25%), and none of 9 paternal grandmothers with known status had the malignancy.

The mechanism for this connection may involve X-chromosome–linked susceptibility genes, the authors wrote. “While the observed absence of ovarian cancer in paternal grandmothers of men with testicular cancer is consistent with X-linked transmission, analyses were limited by small sample sizes and X-linkage could not be conclusively established,” they noted.

An attempt to update the registry and improve the family histories and collection of biospecimens is underway, specifically in families with multiple cases of ovarian cancer as well as at least one case of testicular cancer. “These analyses may provide insight into the etiology of transmission patterns of both cancers and expose novel gene targets for prevention and therapy,” the authors wrote.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content
Advertisement

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Tim Cortese
October 18th 2025
Article

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.


Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.


IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.

IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer

Roman Fabbricatore
September 23rd 2025
Article

IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.


While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Findings from a phase 1 trial and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.

Related Content
Advertisement

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Tim Cortese
October 18th 2025
Article

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.


Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.


IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.

IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer

Roman Fabbricatore
September 23rd 2025
Article

IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.


While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Findings from a phase 1 trial and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.